These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. The prevalence and clinical characteristics of hypersexuality in patients with Parkinson's disease following dopaminergic therapy: A systematic literature review. Nakum S; Cavanna AE Parkinsonism Relat Disord; 2016 Apr; 25():10-6. PubMed ID: 26923525 [TBL] [Abstract][Full Text] [Related]
7. Safinamide for the treatment of Parkinson's disease. deSouza RM; Schapira A Expert Opin Pharmacother; 2017 Jun; 18(9):937-943. PubMed ID: 28504022 [TBL] [Abstract][Full Text] [Related]
8. Safinamide as an adjunct therapy in older patients with Parkinson's disease: a retrospective study. Lo Monaco MR; Petracca M; Vetrano DL; Di Stasio E; Fusco D; Ricciardi D; Laudisio A; Zuccalà G; Onder G; Bentivoglio AR Aging Clin Exp Res; 2020 Jul; 32(7):1369-1373. PubMed ID: 31981101 [TBL] [Abstract][Full Text] [Related]
9. [Hypersexuality in Parkinson's disease. Advantage of the presence of the entourage for medical assessment]. Grandgenevre P; Warembourg F; Carrière N; Vaillant A; Defebvre L; Vaiva G Presse Med; 2015 Mar; 44(3):e51-8. PubMed ID: 25578547 [TBL] [Abstract][Full Text] [Related]
10. Clinical pharmacology review of safinamide for the treatment of Parkinson's disease. Fabbri M; Rosa MM; Abreu D; Ferreira JJ Neurodegener Dis Manag; 2015 Dec; 5(6):481-96. PubMed ID: 26587996 [TBL] [Abstract][Full Text] [Related]
11. Safinamide: first global approval. Deeks ED Drugs; 2015 Apr; 75(6):705-11. PubMed ID: 25851099 [TBL] [Abstract][Full Text] [Related]
12. Safinamide for the treatment of Parkinson's disease. Kandadai RM; Jabeen SA; Kanikannan MA; Borgohain R Expert Rev Clin Pharmacol; 2014 Nov; 7(6):747-59. PubMed ID: 25300164 [TBL] [Abstract][Full Text] [Related]
13. Impulsive-compulsive behaviours in Parkinson's disease--prevention is better than cure. Ryan SA; O'Sullivan SS Ir Med J; 2013 Jun; 106(6):162. PubMed ID: 23909147 [No Abstract] [Full Text] [Related]
14. Safinamide: A Review in Parkinson's Disease. Blair HA; Dhillon S CNS Drugs; 2017 Feb; 31(2):169-176. PubMed ID: 28110399 [TBL] [Abstract][Full Text] [Related]
15. Managing impulse control behaviours in Parkinson's disease: practical guidelines. Macphee GJ; Chaudhuri KR; David AS; Worth P; Wood B Br J Hosp Med (Lond); 2013 Mar; 74(3):160-6. PubMed ID: 23665786 [No Abstract] [Full Text] [Related]
17. Hypersexuality and compulsive over-eating associated with transdermal dopamine agonist therapy. Hinnell C; Hulse N; Martin A; Samuel M Parkinsonism Relat Disord; 2011 May; 17(4):295-6. PubMed ID: 21300562 [No Abstract] [Full Text] [Related]
18. [Hypersexuality and other impulse control disorders in Parkinson's disease]. Nelis EA; Berendse HW; van den Heuvel OA Ned Tijdschr Geneeskd; 2016; 160():A9359. PubMed ID: 26732226 [TBL] [Abstract][Full Text] [Related]
19. Long-term efficacy and safety of safinamide as add-on therapy in early Parkinson's disease. Schapira AH; Stocchi F; Borgohain R; Onofrj M; Bhatt M; Lorenzana P; Lucini V; Giuliani R; Anand R; Eur J Neurol; 2013 Feb; 20(2):271-80. PubMed ID: 22967035 [TBL] [Abstract][Full Text] [Related]
20. Pet killing as a manifestation of impulse control disorder secondary to pramipexol. Micheli F; Pellene A; Arcushin D; Calzinari A; Farret MS Clin Neuropharmacol; 2015; 38(2):55-6. PubMed ID: 25768852 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]